Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects
Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects
Sponsor: Emergent BioSolutions
Terminated
Product development halted for business reasons.
Listed as NCT02696291, this PHASE1 trial focuses on Viral Infection and remains terminated or withdrawn. Sponsored by Emergent BioSolutions, it has been updated 15 times since 2016, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Terminated PHASE1
-
Jan 2023 — Apr 2024 [monthly]
Terminated PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE1
▶ Show 10 earlier versions
-
Dec 2021 — Dec 2022 [monthly]
Terminated PHASE1
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE1
-
Apr 2020 — Jan 2021 [monthly]
Terminated PHASE1
-
Jun 2018 — Apr 2020 [monthly]
Terminated PHASE1
-
Apr 2018 — Jun 2018 [monthly]
Terminated PHASE1
-
Aug 2017 — Apr 2018 [monthly]
Terminated PHASE1
-
Jul 2017 — Aug 2017 [monthly]
Terminated PHASE1
Status: Suspended → Terminated
-
Mar 2017 — Jul 2017 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
May 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Emergent BioSolutions
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .